A new mouse-and-patient study links loss of the X-linked chromatin gene KDM6A to worse cardiac recovery after myocardial infarction, driven by an inflammatory reprogramming of myeloid cells. Researchers report that blocking IL-1β largely rescued the adverse phenotype, tying the mechanism to a targeted inflammatory pathway. The work supports the idea that epigenetic regulators can steer post-infarct immune programs and influence healing outcomes. It also reinforces IL-1β as a clinically actionable axis in post-infarction inflammation. For translational strategy, the study adds a mechanistic rationale for combining cardiometabolic or immunomodulatory approaches with pathway-directed anti-inflammatory interventions.